How do you value a company's assembled clinical trial data in a pharma acquisition?

Full Explanation

Clinical trial data represents a significant intangible asset in pharmaceutical and biotechnology acquisitions because it embodies years of research investment and regulatory advancement. The data itself — patient outcomes, safety profiles, dosing studies, biomarker data — is distinct from the in-process R&D asset (the drug candidate being developed). The cost approach is most commonly used for standalone clinical trial data valuation: estimate the cost of conducting equivalent clinical trials from scratch, including patient recruitment costs, clinical research organisation (CRO) fees, investigator payments, monitoring and compliance costs, data management and analysis, and the time value of money (trial duration can span 3-10 years). A Phase III trial can cost £50-200M+, making the assembled data extremely valuable on a replacement cost basis. When clinical trial data is valued as part of an IPR&D asset, its value is captured through the probability adjustment: a compound with positive Phase II data has a materially higher probability of reaching market (30-40%) than one without data (10-15%), and this probability differential directly increases the IPR&D value. Additional considerations include: data exclusivity periods (regulatory provisions that prevent generic competitors from relying on the originator's trial data for a defined period — typically 8-10 years in the EU and 5-12 years in the US), real-world evidence data (post-marketing surveillance data that supports label expansion and continued regulatory compliance), and the transferability of the data (some trial data may be specific to a particular formulation or indication and have limited applicability to other programmes).

Related Glossary Terms

Related Questions